Source: Eur Respir J, 55 (3) 1901692; 10.1183/13993003.01692-2019



Rating:

Share or cite this content

Citations should be made in the following way:
Cari Stek, Brian Allwood, Elsa Du Bruyn, Jozefien Buyze, Charlotte Schutz, Friedrich Thienemann, Adele Lombard, Robert J. Wilkinson, Graeme Meintjes, Lutgarde Lynen. The effect of HIV-associated tuberculosis, tuberculosis-IRIS and prednisone on lung function. Eur Respir J, 55 (3) 1901692; 10.1183/13993003.01692-2019

Member's Comments

No comment yet.

Related content which might interest you: The effect of prednisone treatment on lung function test parameters in patients with chronic sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 433s Year: 2002 The effect of long term low dose azithromycin on symptoms and lung function in pulmonary sarcoidosis Source: Annual Congress 2008 - Sarcoidosis: pathophysiology and severity Year: 2008 The efficacy of treatment with surfactant-BL (S-BL) in patients with destructive pulmonary tuberculosis Source: Annual Congress 2007 - Research perspectives: diagnosis and treatment of tuberculosis Year: 2007 The impact of long-term azithromycin on antibiotic resistance in HIV-associated chronic lung disease Source: ERJ Open Res, 8 (1) 00491-2021; 10.1183/23120541.00491-2021 Year: 2022 Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis Source: Eur Respir J 2011; 38: 1145-1150 Year: 2011 The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis Year: 2021 The effect of antituberculosis chemotherapy on thyroid hormones in active pulmonary tuberculosis patients Source: Eur Respir J 2001; 18: Suppl. 33, 306s Year: 2001 Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 339s Year: 2001 Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment Source: Eur Respir J 2003; 21: 478-482 Year: 2003 COVID19 coinfection exacerbates lung inflammation in TB patients. Source: Virtual Congress 2021 – Tuberculosis, COVID-19 and other comorbidities Year: 2021 Long-term response to prednisone in newly treated patients with pulmonary sarcoidosis Source: Virtual Congress 2021 – Better understanding of sarcoidosis: new keys Year: 2021 Extrapulmonary tuberculosis in patients with chronic kidney disease receiving renal replacement therapy Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019 Serious infections in sarcoidosis and the effect of treatment Source: International Congress 2019 – Granulomatous disorders: from bench to bedside Year: 2019 Effect of low dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): results from a real life study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Lung function defects in treated pulmonary tuberculosis patients Source: Eur Respir J 2016; 47: 351-352 Year: 2016 Lung function defects in treated pulmonary tuberculosis patients Source: Eur Respir J 2016; 47: 352-353 Year: 2016 The factors associated to pulmonary impairment in patients with treated tuberculosis Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 Long-term lung function follow-up in patients diagnosed and treated for pulmonary tuberculosis Source: Annual Congress 2010 - Prognosis of tuberculosis Year: 2010 Effect of infliximab on lung function and well-being in patients with refractory sarcoidosis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011